POLLARD LAB
What We Do
Work in the Harvey B. Pollard lab primarily focuses on the development of novel drug applications to correct the trafficking defect of mutant Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein, which causes the CF disease phenotype, e.g., lung inflammation, and defined the underlying molecular mechanism processes by which corrective actions is mediated by these candidate drugs. One recent study has shown that inflammation in the COVID-19 airway is due to inhibition of CFTR signaling, and this novel work would significantly make CFTR signaling as an important COVID-related therapeutic target.